For Immediate Release
Alan Barber (202) 293-5380x115
Calculating the Costs of Patent Monopolies and Mismarketing in the Pharmaceutical Industry
WASHINGTON - Patent monopolies provide the pharmaceutical industry with incentives for innovation and research. However, they can also encourage a range of rent-seeking behaviors that impose significant costs.
A new report from the Center for Economic and Policy Research assesses the cost associated with one form of rent-seeking, the mismarketing of drugs. This can occur when a drug company seeks narrow Food and Drug Administration (FDA) approval of a drug then promotes its use for other purposes. In addition, companies may conceal evidence that their drugs are less effective than claimed or possibly even harmful. The authors of the report find that in the case of just five drugs, this form of rent-seeking has resulted in cumulative costs of morbidity and mortality of $382 billion.
The paper, "Patent Monopolies and the Costs of Mismarketing Drugs," examines the cases surrounding the prescription drugs Vioxx, Avandia, Bextra, OxyContin and Zyprexa. In each of these cases, there was either a court ruling against the company or a large settlement paid by the company, evidence that the maker of the drug misrepresented their research to preserve and/or expand the market for the drug in question.
SCROLL TO CONTINUE WITH CONTENT
Never Miss a Beat.
Get our best delivered to your inbox.
For example, the authors' estimates indicate that excess cases of cardiovascular disease and premature death due to the use of Vioxx resulted in lifetime costs of $96 billion. For OxyContin, a drug both aggressively promoted and misbranded as "mildly habit forming," the costs for premature death and abuse-related costs came to $102 billion. In the case of the antipsychotic Zyprexa, drug-maker Eli Lilly downplayed the known side effects of diabetes and obesity while marketing it to children and the elderly—patient groups that were not approved by the FDA. This resulted in 42,600 excess cases of diabetes at a cost of almost $4 billion. Cumulatively, all five cases examined in the paper were estimated to cost $382 billion from 1994 to 2008, or roughly $27 billion a year. This is roughly the same amount the pharmaceutical industry spent on research at the time.
These costs represent a small fraction of the total costs of mismarketing drugs. However, the cases cited in the report suggest that the damage done by mismarketing is quite significant compared to the amount of research induced by patents. This is an indication that there are likely more efficient alternatives to patent-monopoly-supported drug research. An avenue such as publicly financed research could reduce the incentives for harmful rent-seeking behaviors and the consequent social and financial costs.
This is the world we live in. This is the world we cover.
Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.
Please select a donation method:
The Center for Economic and Policy Research (CEPR) was established in 1999 to promote democratic debate on the most important economic and social issues that affect people's lives. In order for citizens to effectively exercise their voices in a democracy, they should be informed about the problems and choices that they face. CEPR is committed to presenting issues in an accurate and understandable manner, so that the public is better prepared to choose among the various policy options.